Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study of the combination of cedazuridine with decitabine in patients with
solid tumors. At least 6 patients will be enrolled per treatment level to assess optimal
hypomethylation and toxicity (up to 30 patients total).
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins